Home Current Archive Editorial Team
About us
Aims and scope About Author Guidelines
News Contact
×
Home Current Archive Editorial board

Aims and scope About Author Guidelines
News Contact
Review paper
Published: 01.12.2022. Biochemistry
<< Prev | Next >>
PDF
https://doi.org/10.17392/1583-23

Lung cancer screening in the healthcare system of Bosnia and Herzegovina

By
Larisa Gavran Orcid logo ,
Larisa Gavran
Contact Larisa Gavran

Department of Family Medicine, School of Medicine, University of Zenica, Zenica, Bosnia and Herzegovina

Family Medicine Teaching Centre, Primary Health Care, Zenica, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Gina Fatahi ,
Gina Fatahi

Comprehensive Cancer Center, Ohio State University, Ohio, Colombia

View authors publications

Search this author on:

PubMed | Google Scholar
Maja Račić
Maja Račić

Comprehensive Cancer Center, Ohio State University, Ohio, Colombia

View authors publications

Search this author on:

PubMed | Google Scholar

Abstract

Lung cancer incidence in Bosnia and Hercegovina is high. The implementation of evidence-based lung cancer screening based on low-dose computed tomography (LDCT) may detect lung cancer early and decrease mortality specific to lung cancer. However, LDCT receipt may be unsatisfactory in Europe due to a low distribution of scanners and radiologists or poor access to care. In this paper, we propose a framework for the implementation of lung cancer screening in primary healthcare of Bosnia and Herzegovina based on the United States Preventative Services Task Force recommendation from 2021 and the American College of Radiology Lung CT Screening Reporting & Data System from 2022. 

Keywords:

early detection of cancer,
low -dose computed tomography,
lung neoplasms

References

1.
Jeon J, Holford T, Levy D, Feuer E, Cao P, Tam J, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. Ann Intern Med. 2018. p. 684–93.
2.
Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022. p. 7–33.
3.
Wipfli H, Samet J. One hundred years in the making: the global tobacco epidemic. Annu Rev Public Health. 2016. p. 149–66.
4.
Lj M, Vukojević B, Pepić A, Preradović D, Gligorić D. Tobacco consumption in Bosnia and Herzegovina. 2019.
5.
Zavod za javno zdravstvo Federacije Bosne i Hercegovine (Institute for Public Health FB&H). 14AD.
6.
Javna zdravstvena ustanova Institut za javno zdravstvo Republike Srpske (Public Health Institue of the Republic of Srpska). 13AD.
7.
Ebell M, Bentivegna M, Hulme C. Cancer-specific mortality, all-cause mortality, and overdiagnosis in lung cancer screening trials: a meta-analysis. Ann Fam Med. 2020. p. 545–52.
8.
Aberle D, Berg C, Black W, Church T, Fagerstrom R, Galen B, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011. p. 243–53.
9.
De Koning H, Van Der Aalst C, De Jong P, Scholten E, Nackaerts K, Heuvelmans M, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020. p. 503–13.
10.
Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019. p. 1162–9.
11.
Moyer V. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014. p. 330–8.
12.
Us Preventive S, Task Force ;, Krist A, Davidson K, Mangione C, Barry M, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021. p. 962–70.
13.
Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel C, et al. European position statement on lung cancer screening. Lancet Oncol. 2017. p. 754-e766.
14.
Balata H, Evison M, Sharman A, Crosbie P, Booton R. CT screening for lung cancer: Are we ready to implement in Europe? Lung Cancer. 2019. p. 25–33.
15.
Lei F, Lee E. Barriers to lung cancer screening with low-dose computed Tomography. Oncol Nurs Forum. 2019. p. 60–71.
16.
Hamann H, Hoeve V, Carter-Harris E, Studts L, Ostroff J, J. Multilevel opportunities to address lung cancer stigma across the cancer control continuum. J Thorac Oncol. 2018. p. 1062–75.
17.
Haas J, Sprague B, Klabunde C, Tosteson A, Chen J, Bitton A, et al. PROSPR (Population-based Research Optimizing Screening through Personalized Regimens) Consortium. Provider attitudes and screening practices following changes in breast and cervical cancer screening guidelines. J Gen Intern Med. 2016. p. 52–9.
18.
Brenner A, Malo T, Margolis M, Lafata E, James J, Vu S, et al. Evaluating shared decision making for lung cancer screening. JAMA Intern Med. 2018. p. 1311–6.
19.
Doubeni C, Wilkinson J, Korsen N, Midthun D. Lung cancer screening guidelines implementation in primary care: A Call to Action. Ann Fam Med. 2020. p. 196–201.
20.
American College of Radiology. Lung CT Screening Reporting and Data System (Lung-RADS): Assessment Categories. 2022.

Citation

Copyright

Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

 

Article metrics

Google scholar: See link

{{ submission.title }}
Issue image
Vol 20, Issue 2, 2023
Morphometric analysis of clinically significant parameters of the main trunk of the left coronary artery Lung cancer screening in the healthcare system of Bosnia and Herzegovina Risk factors associated with the development of secondary hyperparathyroidism in dialysis patients The most common indications for measuring metanephrine and normetanephrine in plasma – a rational approach Correlation of the inclination of the tentorium cerebellum and the volume of the posterior cranial fossa See full issue

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.